Cochlear's 1H Profit Drops 21% After Price Rise Negotiations -- Update

Dow Jones
02/13
 

By Stuart Condie

 

SYDNEY--Cochlear expects an annual profit at the lower end of its guidance range after negotiations over pricing slowed the rollout of its latest hearing system, contributing to a 21% drop in first-half profit.

The Australian hearing-tech developer on Friday reported a net profit for the six months through December of 161.5 million Australian dollars, equivalent to US$115.2 million. That compared with A$205.1 million a year earlier.

Sales revenue rose by 1% to A$1.18 billion, but fell by 2% once currency moves were stripped out. The company held its dividend at A$2.15.

The average analyst forecast had been for a net profit of A$178.1 million from sales revenue of A$1.22 billion, according to data compiled by Visible Alpha.

"The first half result reflects the product registration and contract renewal process for the new system, which took longer than anticipated where we sought price increases," said Cochlear, adding the process was largely complete.

Underlying net profit for the December half fell 10% in constant currency terms to A$194.8 million. Cochlear said it expects full-year underlying net profit at the lower end of its previously issued A$435 million-A$460 million guidance range.

Cochlear, which developed the world's first hearing implant in the 1970s after its founder experimented with a blade of grass inside a shell found on an Australian beach, also called out the revenue impact from the sale of cheaper products in emerging markets.

Total implant volumes grew 6% on year to 27,016, but implant sales revenue was flat at A$724.0 million, or 2% lower once currency moves were stripped out. Emerging-market volumes rose 15% on a year earlier.

 

Write to Stuart Condie at stuart.condie@wsj.com

 

(END) Dow Jones Newswires

February 12, 2026 17:01 ET (22:01 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

应版权方要求,你需要登录查看该内容

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10